Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Equity Average (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Equity Average over the past 15 years, most recently at $1.8 million for Q2 2025.

  • Quarterly results put Equity Average at $1.8 million for Q2 2025, down 87.71% from a year ago — trailing twelve months through May 2025 was $1.8 million (down 87.71% YoY), and the annual figure for FY2025 was $6.3 million, up 78.56%.
  • Equity Average for Q2 2025 was $1.8 million at Lifecore Biomedical, Inc. \De\, down from $8.8 million in the prior quarter.
  • Over the last five years, Equity Average for LFCR hit a ceiling of $205.1 million in Q1 2021 and a floor of -$8.9 million in Q3 2023.
  • Median Equity Average over the past 5 years was $34.2 million (2023), compared with a mean of $72.1 million.
  • Biggest five-year swings in Equity Average: tumbled 110.74% in 2023 and later surged 194.82% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Equity Average stood at $174.3 million in 2021, then tumbled by 57.25% to $74.5 million in 2022, then plummeted by 108.15% to -$6.1 million in 2023, then surged by 194.82% to $5.8 million in 2024, then plummeted by 69.03% to $1.8 million in 2025.
  • The last three reported values for Equity Average were $1.8 million (Q2 2025), $8.8 million (Q1 2025), and $5.8 million (Q4 2024) per Business Quant data.